Shattuck Labs (STTK) Competitors

Shattuck Labs logo
$4.46 -0.09 (-1.98%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$4.46 0.00 (-0.11%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

STTK vs. REPL, TRAX, COAG, MAZE, and AGIO

Should you buy Shattuck Labs stock or one of its competitors? Shattuck Labs's main competitors and comparable companies include Replimune Group (REPL), First Tracks Biotherapeutics (TRAX), Hemab Therapeutics (COAG), Maze Therapeutics (MAZE), and Agios Pharmaceuticals (AGIO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Shattuck Labs compare to Replimune Group?

Shattuck Labs (NASDAQ:STTK) and Replimune Group (NASDAQ:REPL) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings.

Shattuck Labs has a beta of 1.21, meaning that its share price is 21% more volatile than the broader market. Comparatively, Replimune Group has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market.

Shattuck Labs presently has a consensus target price of $13.70, indicating a potential upside of 207.17%. Replimune Group has a consensus target price of $18.17, indicating a potential downside of 4.74%. Given Shattuck Labs' stronger consensus rating and higher probable upside, analysts clearly believe Shattuck Labs is more favorable than Replimune Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Shattuck Labs
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
3 Strong Buy rating(s)
3.08
Replimune Group
2 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.50

In the previous week, Replimune Group had 12 more articles in the media than Shattuck Labs. MarketBeat recorded 14 mentions for Replimune Group and 2 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 0.90 beat Replimune Group's score of 0.30 indicating that Shattuck Labs is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Shattuck Labs
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Replimune Group
5 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Shattuck Labs is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Shattuck LabsN/AN/A-$48.81M-$0.51N/A
Replimune GroupN/AN/A-$313.94M-$2.79N/A

Shattuck Labs' return on equity of -46.46% beat Replimune Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Shattuck LabsN/A -46.46% -43.56%
Replimune Group N/A -157.78%-83.89%

58.7% of Shattuck Labs shares are owned by institutional investors. Comparatively, 92.5% of Replimune Group shares are owned by institutional investors. 8.8% of Shattuck Labs shares are owned by insiders. Comparatively, 5.4% of Replimune Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Shattuck Labs beats Replimune Group on 11 of the 14 factors compared between the two stocks.

How does Shattuck Labs compare to First Tracks Biotherapeutics?

First Tracks Biotherapeutics (NASDAQ:TRAX) and Shattuck Labs (NASDAQ:STTK) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, valuation and dividends.

First Tracks Biotherapeutics' return on equity of 0.00% beat Shattuck Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
First Tracks BiotherapeuticsN/A N/A N/A
Shattuck Labs N/A -46.46%-43.56%

In the previous week, Shattuck Labs had 1 more articles in the media than First Tracks Biotherapeutics. MarketBeat recorded 2 mentions for Shattuck Labs and 1 mentions for First Tracks Biotherapeutics. Shattuck Labs' average media sentiment score of 0.90 beat First Tracks Biotherapeutics' score of 0.67 indicating that Shattuck Labs is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
First Tracks Biotherapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Shattuck Labs
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

First Tracks Biotherapeutics presently has a consensus target price of $72.17, indicating a potential upside of 73.31%. Shattuck Labs has a consensus target price of $13.70, indicating a potential upside of 207.17%. Given Shattuck Labs' stronger consensus rating and higher possible upside, analysts plainly believe Shattuck Labs is more favorable than First Tracks Biotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
First Tracks Biotherapeutics
1 Sell rating(s)
1 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.79
Shattuck Labs
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
3 Strong Buy rating(s)
3.08

58.7% of Shattuck Labs shares are owned by institutional investors. 8.8% of Shattuck Labs shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

First Tracks Biotherapeutics is trading at a lower price-to-earnings ratio than Shattuck Labs, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
First Tracks BiotherapeuticsN/AN/AN/A-$2.79N/A
Shattuck LabsN/AN/A-$48.81M-$0.51N/A

Summary

Shattuck Labs beats First Tracks Biotherapeutics on 9 of the 12 factors compared between the two stocks.

How does Shattuck Labs compare to Hemab Therapeutics?

Hemab Therapeutics (NASDAQ:COAG) and Shattuck Labs (NASDAQ:STTK) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation.

58.7% of Shattuck Labs shares are held by institutional investors. 8.8% of Shattuck Labs shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Hemab Therapeutics' return on equity of 0.00% beat Shattuck Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
Hemab TherapeuticsN/A N/A N/A
Shattuck Labs N/A -46.46%-43.56%

In the previous week, Shattuck Labs had 1 more articles in the media than Hemab Therapeutics. MarketBeat recorded 2 mentions for Shattuck Labs and 1 mentions for Hemab Therapeutics. Hemab Therapeutics' average media sentiment score of 1.02 beat Shattuck Labs' score of 0.90 indicating that Hemab Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Hemab Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Shattuck Labs
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Shattuck Labs is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hemab TherapeuticsN/AN/AN/A-$25.36N/A
Shattuck LabsN/AN/A-$48.81M-$0.51N/A

Hemab Therapeutics presently has a consensus price target of $56.00, indicating a potential upside of 42.53%. Shattuck Labs has a consensus price target of $13.70, indicating a potential upside of 207.17%. Given Shattuck Labs' stronger consensus rating and higher possible upside, analysts clearly believe Shattuck Labs is more favorable than Hemab Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hemab Therapeutics
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.70
Shattuck Labs
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
3 Strong Buy rating(s)
3.08

Summary

Shattuck Labs beats Hemab Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Shattuck Labs compare to Maze Therapeutics?

Maze Therapeutics (NASDAQ:MAZE) and Shattuck Labs (NASDAQ:STTK) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Shattuck Labs has lower revenue, but higher earnings than Maze Therapeutics. Maze Therapeutics is trading at a lower price-to-earnings ratio than Shattuck Labs, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Maze Therapeutics$167.50M10.23-$131.12M-$2.65N/A
Shattuck LabsN/AN/A-$48.81M-$0.51N/A

Maze Therapeutics has a beta of 2.04, suggesting that its share price is 104% more volatile than the broader market. Comparatively, Shattuck Labs has a beta of 1.21, suggesting that its share price is 21% more volatile than the broader market.

Maze Therapeutics' return on equity of -38.39% beat Shattuck Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
Maze TherapeuticsN/A -38.39% -32.57%
Shattuck Labs N/A -46.46%-43.56%

In the previous week, Maze Therapeutics and Maze Therapeutics both had 2 articles in the media. Shattuck Labs' average media sentiment score of 0.90 beat Maze Therapeutics' score of 0.63 indicating that Shattuck Labs is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Maze Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Shattuck Labs
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Maze Therapeutics presently has a consensus target price of $65.50, indicating a potential upside of 109.00%. Shattuck Labs has a consensus target price of $13.70, indicating a potential upside of 207.17%. Given Shattuck Labs' higher possible upside, analysts clearly believe Shattuck Labs is more favorable than Maze Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Maze Therapeutics
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
3 Strong Buy rating(s)
3.08
Shattuck Labs
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
3 Strong Buy rating(s)
3.08

58.7% of Shattuck Labs shares are owned by institutional investors. 5.3% of Maze Therapeutics shares are owned by company insiders. Comparatively, 8.8% of Shattuck Labs shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Shattuck Labs beats Maze Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Shattuck Labs compare to Agios Pharmaceuticals?

Shattuck Labs (NASDAQ:STTK) and Agios Pharmaceuticals (NASDAQ:AGIO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Shattuck Labs presently has a consensus price target of $13.70, suggesting a potential upside of 207.17%. Agios Pharmaceuticals has a consensus price target of $41.63, suggesting a potential upside of 50.82%. Given Shattuck Labs' stronger consensus rating and higher possible upside, analysts plainly believe Shattuck Labs is more favorable than Agios Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Shattuck Labs
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
3 Strong Buy rating(s)
3.08
Agios Pharmaceuticals
1 Sell rating(s)
3 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.60

Shattuck Labs has a beta of 1.21, meaning that its share price is 21% more volatile than the broader market. Comparatively, Agios Pharmaceuticals has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market.

58.7% of Shattuck Labs shares are owned by institutional investors. 8.8% of Shattuck Labs shares are owned by company insiders. Comparatively, 5.4% of Agios Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Shattuck Labs has higher earnings, but lower revenue than Agios Pharmaceuticals. Shattuck Labs is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Shattuck LabsN/AN/A-$48.81M-$0.51N/A
Agios Pharmaceuticals$54.03M30.55-$412.78M-$6.32N/A

Shattuck Labs has a net margin of 0.00% compared to Agios Pharmaceuticals' net margin of -264.76%. Agios Pharmaceuticals' return on equity of -34.63% beat Shattuck Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
Shattuck LabsN/A -46.46% -43.56%
Agios Pharmaceuticals -264.76%-34.63%-32.04%

In the previous week, Agios Pharmaceuticals had 3 more articles in the media than Shattuck Labs. MarketBeat recorded 5 mentions for Agios Pharmaceuticals and 2 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 0.90 beat Agios Pharmaceuticals' score of -0.31 indicating that Shattuck Labs is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Shattuck Labs
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Agios Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Shattuck Labs beats Agios Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

Get Shattuck Labs News Delivered to You Automatically

Sign up to receive the latest news and ratings for STTK and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

STTK vs. The Competition

MetricShattuck LabsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$454.22M$3.92B$7.44B$10.86B
Dividend YieldN/A3.79%2.51%4.69%
P/E Ratio-8.7523.0732.5628.72
Price / SalesN/A15.358.005.34
Price / CashN/A21.9220.2520.77
Price / Book2.354.124.343.51
Net Income-$48.81M-$24.08M$3.51B$394.12M
7 Day Performance-4.09%-9.85%-8.07%-8.97%
1 Month Performance-20.36%-12.77%-10.29%-11.61%
1 Year Performance119.70%-7.99%-4.70%-11.21%

Shattuck Labs Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
STTK
Shattuck Labs
2.3159 of 5 stars
$4.46
-2.0%
$13.70
+207.2%
+119.7%$454.22MN/AN/A40
REPL
Replimune Group
1.4573 of 5 stars
$19.69
-8.0%
$18.17
-7.7%
+107.3%$1.87BN/AN/A465
TRAX
First Tracks Biotherapeutics
3.3291 of 5 stars
$43.57
-6.4%
$72.17
+65.6%
N/A$1.83BN/AN/A104
COAG
Hemab Therapeutics
2.7417 of 5 stars
$39.06
flat
$56.00
+43.4%
N/A$1.83BN/AN/A59
MAZE
Maze Therapeutics
2.9535 of 5 stars
$32.87
-3.0%
$65.50
+99.3%
-13.6%$1.80B$167.50MN/A141

Related Companies and Tools


This page (NASDAQ:STTK) was last updated on 11/22/2026 by MarketBeat.com Staff.
From Our Partners